Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Chen, Chang, Zhang, Yi, Huang, Jianying, Yin, Ping, Cheng, Zhenshun, Wu, Jianyuan, Chen, Song, Zhang, Yongxi +6 more·2020·Frontiers in Pharmacology
DOI 10.1101/2020.03.17.20037432

Cited by (675)

Items 101–200 of 675

  1. Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients
    A. Alemany, B. Baro, D. Ouchi et al. · 2020 · Journal of Infection
  2. COVID-19 Therapeutic Options Under Investigation
    Malak Kaddoura, Malak Al Ibrahim, Ghina Hijazi, Nadia Soudani, Amani Audi, Habib Alkalamouni, Salame Haddad, Ali Hussein Eid, Hassan Zaraket · 2020 · Frontiers in Pharmacology
  3. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
    Ghada Algwaiz, Mahmoud Deeb Aljurf, Mickey Koh, Mary M. Horowitz, Per T Ljungman, Daniel Jordan Weisdorf, Wael Saber, Yoshihisa Kodera, Jeff Szer, Dunia M. Jawdat et al. · 2020 · Transplantation and Cellular Therapy
  4. Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury
    M. Sise, Meridale V. Baggett, J. Shepard · 2020 · New England Journal of Medicine
  5. COVID-19 pandemic: A review based on current evidence
    Bikash Medhi, VidyaM Mahalmani, Dhruv Mahendru, Ankita Semwal, Sukhmeet Kaur, Harpinder Kaur, Phulen Sarma, Ajay Prakash · 2020 · Indian Journal of Pharmacology
  6. An overview on the treatments and prevention against COVID-19
    Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, Fatemeh Beiraghdar, Abolfazl Akbarzadeh, Vahideh Tarhriz, Hassan Mellatyar · 2023 · Virology Journal
  7. The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies
    Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, Abdelrahman M Makram, Gehad Mohamed Tawfik, Ali Ahmed‐Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage et al. · 2022 · International Journal of Infectious Diseases
  8. Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database
    Rimple Jeet Kaur, Jaykaran Charan, Siddhartha Dutta, Paras Sharma, Pankaj Bhardwaj, Praveen Sharma, Halyna Lugova, Ambigga Devi S. Krishnapillai, Salequl Islam, Mainul Haque et al. · 2020 · Infection and Drug Resistance
  9. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
    Xiaosheng Liu, Wei Cao, Taisheng Li · 2020 · Frontiers in Immunology
  10. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs
    Alessandra Bartoli, Filippo Gabrielli, Tatiana Alicandro, Fabio Nascimbeni, Pietro Andreoné · 2021 · Internal and Emergency Medicine
  11. Tackling SARS-CoV-2: Proposed Targets and Repurposed Drugs
    Siddhi S. Joshi, Maithili Joshi, Mariam Sohel Degani · 2020 · Future Medicinal Chemistry
  12. Therapeutic Management of COVID-19 Patients: A systematic review
    Mansour A. Tobaiqy, M. Qashqary, S. Al-Dahery · 2020 · medRxiv
  13. An update review of emerging small-molecule therapeutic options for COVID-19
    Dengke Tian, Yuzhi Liu, Chengyuan Liang, Liang Xin, Xiaolin Xie, Dezhu Zhang, Minge Wan, Han Li, Xueqi Fu, Hong Liu et al. · 2021 · Biomedicine & Pharmacotherapy
  14. Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
    Abdullahi Rabiu Abubakar, Ibrahim Haruna Sani, Brian Godman, Santosh Kumar, Salequl Islam, Iffat Jahan, Mainul Haque · 2020 · Infection and Drug Resistance
  15. COVID-19: Therapeutics and interventions currently under consideration
    R. McFee · 2020 · Disease-a-month : DM
  16. A Perspective on Emerging Therapeutic Interventions for COVID-19
    Muhammad Torequl Islam, Md Nasiruddin, Ishaq Nasib Khan, Siddhartha Kumar Mishra, Md. Kudrat‐E‐Zahan, Thoufiqul Alam Riaz, Eunus Sheemul Ali, M. Safiur Rahman, Mohammad Suleiman Mubarak, Miquel Martorell et al. · 2020 · Frontiers in Public Health
  17. Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trial
    Seyed Abbas Mousavi, Keyvan Heydari, Hossein Mehravaran, Majid Saeedi, Reza Alizadeh‐Navaei, Akbar Hedayatizadeh‐Omran, Amir Shamshirian · 2021 · Journal of Medical Virology
  18. Repurposing drugs for the management of COVID-19
    Jacopo Cusinato, Ylenia Cau, Anna Maria Calvani, Mattia Mori · 2020 · Expert Opinion on Therapeutic Patents
  19. Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study
    Debanjan Sen, Pradip Debnath, Bimal Debnath, Samhita Bhaumik, Sudhan Debnath · 2020 · Journal of Biomolecular Structure and Dynamics
  20. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor
    Eduardo L Feitosa, Francisco Tiago Dos S S Júnior, José Arimatéa de Oliveira Nery Neto, Luis F L Matos, Matheus Henrique de Sousa Moura, Thiele Osvaldt Rosales, Guilherme Barroso L. De Freitas · 2020 · International Journal of Medical Sciences
  21. Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners
    Ioana Roxana Bordea, Edit Xhajanka, Sebastian Candrea, Simion Bran, Florin Gligor Onisor, Alessio Danilo Inchingolo, Giuseppina Malcangi, Van Hung Pham, Angelo Michele Inchingolo, Antônio Scarano et al. · 2020 · Microorganisms
  22. Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
    Fajgenbaum, David C., Khor, Johnson S., Gorzewski, Alexander, Tamakloe, Mark-Avery, Powers, Victoria, Kakkis, Joseph J., Repasky, Mileva, Taylor, Anne, Beschloss, Alexander, Hernandez-Miyares, Laura et al. · 2020 · Infectious Diseases and Therapy
  23. Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19
    Sara Lega, Samuele Naviglio, Stefano Volpi, Alberto Tommasini · 2020 · Vaccines
  24. Solubility of favipiravir (as an anti-COVID-19) in supercritical carbon dioxide: An experimental analysis and thermodynamic modeling
    Seyed Ali Sajadian, Nedasadat Saadati Ardestani, Nadia Esfandiari, Mahshid Askarizadeh, Abolghasem Jouyban · 2022 · The Journal of Supercritical Fluids
  25. Risk of mortality in COVID-19 patients: a meta- and network analysis
    Rasoul Kowsar, Amir Mohammad Rahimi, Magdalena Sroka, Alireza Mansouri, Khaled Sadeghi, Elham Bonakdar, Sayed Farshad Kateb, Amir Hossein Mahdavi · 2023 · Scientific Reports
  26. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
    Sophie Juul, Emil Eik Nielsen, Joshua Buron Feinberg, Faiza Siddiqui, Caroline Barkholt Kamp, Emily Barot, Johan Holgersson, Niklas Nielsen, Peter Bentzer, Areti Angeliki Veroniki et al. · 2021 · PLoS ONE
  27. COVID ‐19: a brief history and treatments in development
    Steve Chaplin · 2020 · Prescriber
  28. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline
    Zhikang Ye, Bram N. Rochwerg, Ying Wang, Neill K. J. Adhikari, Srinivas Murthy, François Lamontagne, Robert Fowler, Haibo Qiu, Wei Li, Ling Sang et al. · 2020 · Canadian Medical Association Journal
  29. SARS-CoV-2: Targeted managements and vaccine development
    Moiz Bakhiet, Sébastien Taurin · 2020 · Cytokine & Growth Factor Reviews
  30. A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
    Po‐Lin Chen, Nan–Yao Lee, Cong-Tat Cia, Wen‐Chien Ko, Po‐Ren Hsueh · 2020 · Frontiers in Pharmacology
  31. A systematic review assessing the under-representation of elderly adults in COVID-19 trials
    on behalf of ESCMID Study Group for Infections in the Elderly (ESGIE), Virginie Prendki, Noam Tau, Tomer Avni, Marco Falcone, Angela Csaki Huttner, Laurent Kaiser, Mical Paul, Yaara Leibovici Weissman, Dafna Yahav · 2020 · BMC Geriatrics
  32. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda
    Bruce Kirenga, Winters Muttamba, Alex Kayongo, Christopher Nsereko, Trishul Siddharthan, John Kafuluma Lusiba, Levicatus Mugenyi, Rosemary Kusaba Byanyima, William O. Worodria, Fred Nakwagala et al. · 2020 · BMJ Open Respiratory Research
  33. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
    Namrta Choudhry, Xin Zhao, Dan Xu, Mark Zanin, Weisan Chen, Zifeng Yang, Jianxin Chen · 2020 · Journal of Medicinal Chemistry
  34. Advances in the possible treatment of COVID-19: A review.
    Pankaj Chibber, Syed Assim Haq, Irfan Ahmed, Nusrit Iqbal Andrabi, Gurdarshan Singh · 2020 · European Journal of Pharmacology
  35. Overview of therapeutic drug research for COVID-19 in China
    Heng Li, Li Yang, Fei-fei Liu, Xin-na Ma, Pei‐Lan He, Wei Tang, Xiankun Tong, Jianping Zuo · 2020 · Acta Pharmacologica Sinica
  36. Identification of COVID-19 prognostic markers and therapeutic targets through meta-analysis and validation of Omics data from nasopharyngeal samples
    Abhijith Biji, Oyahida Khatun, Shachee Swaraj, Rohan Narayan, Raju S Rajmani, Rahila Sardar, Deepshikha Satish, Simran Mehta, Hima Bindhu, Madhumol Jeevan et al. · 2021 · EBioMedicine
  37. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials
    Rami A. Al‐Horani, Srabani Kar, Kholoud F. Aliter · 2020 · International Journal of Molecular Sciences
  38. An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    S. Al-Azzam, N. Mhaidat, H. Banat · 2021 · Antibiotics
  39. Precision therapeutic targets for COVID-19
    Zachary A. Krumm, Grace M. Lloyd, Connor P. Francis, Lith H. Nasif, Duane A. Mitchell, Todd Eliot Golde, Benoit I. Giasson, Yuxing Xia · 2021 · Virology Journal
  40. COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa
    Bisi Bright, Chinedum Peace Babalola, Nadia Adjoa Sam-Agudu, Augustine Anayochukwu Onyeaghala, Adebola Olatunji, Ufuoma Aduh, Patrick O. Sobande, Trevor A. Crowell, Yenew Kebede Tebeje, Sunny Phillip et al. · 2021 · Globalization and Health
  41. Therapeutic strategies to fight COVID‐19: Which is the status artis?
    Cristina Scavone, Annamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, Ugo Trama, Alice Zoccoli, Francesca Futura Bernardi, Giorgio Racagni, Liberato Berrino, Giuseppe Castaldo et al. · 2021 · British Journal of Pharmacology
  42. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
    Ye-Ming Wang, Wu Zhong, A. Salam et al. · 2020 · EBioMedicine
  43. Pathogenesis‐directed therapy of 2019 novel coronavirus disease
    Charles W. Stratton, Yi‐Wei Tang, Hongzhou Lu · 2020 · Journal of Medical Virology
  44. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
    Sirle Saul, Shirit Einav · 2020 · ACS Infectious Diseases
  45. Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
    Hosoki, Koa, Chakraborty, Abhijit, Sur, Sanjiv · 2020 · Journal of Allergy and Clinical Immunology
  46. Treatment of SARS-CoV-2: How far have we reached?
    Waquar Ahsan, Shamama Javed, Mohammed Al Bratty, Hassan A. Alhazmi, Asim Najmi · 2020 · Drug Discoveries & Therapeutics
  47. Drug repurposing and cytokine management in response to COVID-19: A review
    Luana Heimfarth, Mairim Russo Serafini, Paulo Ricardo Martins‐Filho, Jullyana de Souza Siqueira Quintans, Lucindo José Quintans‐Júnior · 2020 · International Immunopharmacology
  48. Development of Metal Complexes for Treatment of Coronaviruses
    Hany M. Abd El‐Lateef, Tarek El‐Dabea, Mai M. Khalaf, Ahmed M. Abu‐Dief · 2022 · International Journal of Molecular Sciences
  49. Repurposing of FDA ‐approved drugs against active site and potential allosteric drug‐binding sites of COVID ‐19 main protease
    Merve Yuce, Erdem Çiçek, Tuğçe İnan, Aslıhan Başak Dağ, Özge Kürkçüoğlu, Fethiye Aylin Sungur · 2021 · Proteins Structure Function and Bioinformatics
  50. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment
    Fiona Marra, Elise Joëlle Smolders, Omar El‐Sherif, Alison Boyle, Katherine Davidson, Andrew Sommerville, Catia Marzolini, Marco Siccardi, David Burger, Sara Gibbons et al. · 2020 · Drugs in R&D
  51. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics
    Ramesh J. L. Kandimalla, Albin A John, Chandrika Abburi, Jayalakshmi Vallamkondu, P. Hemachandra Reddy · 2020 · Molecular Neurobiology
  52. Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review
    Parisa Ghasemiyeh, Afshin Borhani‐Haghighi, Iman Karimzadeh, Soliman Mohammadi‐Samani, Afsaneh Vazin, Anahid Safari, Adnan Iqbal Qureshi · 2020 · Therapeutics and Clinical Risk Management
  53. A review on favipiravir: the properties, function, and usefulness to treat COVID-19
    Seyed Mohammad Reza Hashemian, Tayebeh Farhadi, Ali Akbar Velayati · 2020 · Expert Review of Anti-infective Therapy
  54. Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
    Burak Berber, Cihan Aydın, Fatih Kocabaş, Gülen Güney-Esken, Kaan Yılancıoğlu, Medine Karadag Alpaslan, Mehmet Çalıseki, Melek Yüce, Sevda Demir, Cihan Taştan · 2020 · Gene Therapy
  55. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
    Cristina Adriana Dehelean, Voichița Elena Lăzureanu, Dorina Elena Coricovac, Marius Mioc, Roxana Oancea, Iasmina Marcovici, Iulia Pînzaru, Codruţa Şoica, Aristidis Michael Tsatsakis, Octavian Marius Cretu · 2020 · Journal of Clinical Medicine
  56. Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community
    Zichao Luo, Melgious Jin Yan Ang, Siew Yin Chan, Zhigao Yi, Yi Yiing Goh, Shuangqian Yan, Jun Tao, Kai Liu, Xiaosong Li, Hongjie Zhang et al. · 2020 · Research
  57. Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery
    Zhonglei Wang, Liyan Yang, Xian‐En Zhao · 2021 · Computational and Structural Biotechnology Journal
  58. A Narrative Review of COVID-19: The New Pandemic Disease.
    Kiana Shirani, Erfan Sheikhbahaei, Zahra Torkpour, Mazyar Ghadiri Nejad, Bahareh Kamyab Moghadas, Matina Ghasemi, Hossein Akbari Aghdam, Athena Ehsani, Saeed Saber‐Samandari, Amirsalar Khandan · 2020 · PubMed Central
  59. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines
    Annoor Awadasseid, Yanling Wu, Yoshimasa Tanaka, Wen Zhang · 2021 · Biomedicine & Pharmacotherapy
  60. Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review
    Rami A. Al‐Horani, Srabani Kar · 2020 · Viruses
  61. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19
    Shalki Choudhary, Om Silakari · 2020 · Virus Research
  62. Pharmacological treatments of COVID-19
    Adeleh Sahebnasagh, Razieh Avan, Fatemeh Saghafi, Mojataba Mojtahedzadeh, Afsaneh Sadremomtaz, Omid Arasteh, Asal Tanzifi, Fatemeh Faramarzi, Reza Negarandeh, Mohammadreza Safdari et al. · 2020 · Pharmacological Reports
  63. Current pharmacological treatments for SARS-COV-2: A narrative review
    Giulio Nittari, Graziano Pallotta, Francesco Amenta, Seyed Khosrow Tayebati · 2020 · European Journal of Pharmacology
  64. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta
    Diana Laila Ramatillah, Suri Isnaini · 2021 · PLoS ONE
  65. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection
    Chang Li, Lin Wang, Lin-Zhu Ren · 2020 · Virus Research
  66. Interim Guidelines on Antiviral Therapy for COVID-19
    Sun Bean Kim, Kyungmin Huh, Jung Yeon Heo, Eun‐Jeong Joo, Youn Jeong Kim, Won Suk Choi, Yae‐Jean Kim, Yu Bin Seo, Young Kyung Yoon, Nam Su Ku et al. · 2020 · Infection and Chemotherapy
  67. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study
    Zeynab Mohamadi Yarijani, Houshang Najafi · 2021 · Biomedicine & Pharmacotherapy
  68. Potential health benefits of zinc supplementation for the management of COVID‐19 pandemic
    Ademola Adetokunbo Oyagbemi, Temitayo Olabisi Ajibade, Yapo Guillaume Aboua, Idayat Titilayo Gbadamosi, Aduragbenro Deborah A. Adedapo, Abimbola Obemisola Aro, Olumuyiwa Abiola Adejumobi, Emma Katengua-Thamahane, Temidayo Olutayo Omóbòwálé, Olufunke Olubunmi Falayi et al. · 2021 · Journal of Food Biochemistry
  69. Plant-Based Drugs and Vaccines for COVID-19
    Nasir Mahmood, Sarah Bushra Nasir, Kathleen Laura Hefferon · 2020 · Vaccines
  70. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021
    Safaet Alam, Taslima Binte Kamal, Md. Moklesur Rahman Sarker, Jin‐Rong Zhou, S. M. Abdur Rahman, Isa Naina Mohamed · 2021 · Frontiers in Pharmacology
  71. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
    Jimin Xu, Yu Xue, Richard Zhou, Pei‐Yong Shi, Hongmin Li, Jia Zhou · 2020 · Medicinal Research Reviews
  72. Diagnostic and Treatment Strategies for COVID-19
    Humzah Jamshaid, Fatima Zahid, Intisar ud Din, Alam Zeb, Han Gon Choi, Gul Majid Khan, Fakhar ud Din · 2020 · AAPS PharmSciTech
  73. Revisiting potential druggable targets against SARS‐CoV ‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
    Abdullah Al Mamun Sohag, Md. Abdul Hannan, Sadaqur Rahman, Motaher Hossain, Mahmudul Hasan, Md Kawsar Khan, Amena Khatun, Raju Dash, Md Jamal Uddin · 2020 · Drug Development Research
  74. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
    Matteo Bassetti, Daniele Roberto Giacobbe, Stefano Aliberti, Emanuela Barisione, Stefano Centanni, Francesco Giuseppe De Rosa, Fabiano Di Marco, Andrea Gori, Guido Granata, Małgorzata Mikulska et al. · 2020 · Clinical Microbiology and Infection
  75. Millennium pandemic: A review of coronavirus disease (COVID-19)
    Satılmış Bilgin, Ozge Kurtkulagi, G. Kahveci · 2020
  76. Drug treatments for covid-19: living systematic review and network meta-analysis
    Anonymous · 2021 · British medical journal
  77. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses
    Maike Sperk, Robert van Domselaar, Jimmy Rodriguez Murillo, Flora Mikaeloff, Beatriz Sá Vinhas, Elisa Saccon, Anders B. Sönnerborg, Kamal Deep Singh, Soham Gupta, Ákos Végvári et al. · 2020 · Journal of Proteome Research
  78. Test on stool samples improves the diagnosis of hospitalized patients: Detection of SARS-CoV-2 genomic and subgenomic RNA
    Luiz Vinícius Leão Moreira, Luciano Kleber de Souza Luna, Gabriela Rodrigues Barbosa, Ana Helena Perosa, Ana Paula Cunha Chaves, D. Conte, Joseane Mayara Almeida Carvalho, Nancy Bellei · 2020 · Journal of Infection
  79. Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke
    Chien-Chih Wang, Jian-Kang Chao, Mong-Lien Wang · 2020 · Journal of Stroke & Cerebrovascular Diseases
  80. Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications.
    Fulvio Lauretani, Giulia Ravazzoni, Maria Federica Roberti, Yari Longobucco, Elisa Adorni, Margherita Grossi, Aurelio De Iorio, Umberto La Porta, Chiara De Fazio, Elena Gallini et al. · 2020 · Acta bio-medica dell'Ateneo parmense/Acta biomedica
  81. A detailed review of the outbreak of COVID-19
    Kabita Das, M. Shivapriya Pingali, Biswaranjan Paital, Falguni Panda, Samar Gourav Pati, Anirudh K. Singh, Pritish Kumar Varadwaj, Sintu Kumar Samanta · 2021 · Frontiers in Bioscience-Landmark
  82. The Anti-Viral and Anti-Inflammatory Properties of Edible Bird’s Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application
    Kien Hui Chua, Isa Naina Mohamed, Mohd Heikal Mohd Yunus, Norefrina Shafinaz Md Nor, Khidhir Kamil, Azizah Ugusman, Jaya Kumar · 2021 · Frontiers in Pharmacology
  83. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
    Suresh Kumar, Rosemarie de Souza, Milind Nadkar, Randeep Guleria, Anjan Trikha, Shashank Joshi, Subramanian Loganathan, Sivakumar Vaidyanathan, Ashwani Marwah, Sandeep N. Athalye · 2021 · Expert Opinion on Biological Therapy
  84. The “sex gap” in COVID-19 trials: a scoping review
    Veronique M. M. M. Schiffer, Emma B N J Janssen, Bas C. T. van Bussel, Laura M Jorissen, Jeanette Tas, Jan-Willem E. M. Sels, Dennis C. J. J. Bergmans, Trang Dinh, Sander M. J. van Kuijk, Anisa Hana et al. · 2020 · EClinicalMedicine
  85. Drugs against SARS‐CoV ‐2: What do we know about their mode of action?
    Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean‐Claude Guillemot, Bruno Coutard, Étienne Decroly · 2020 · Reviews in Medical Virology
  86. A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing
    K. Deepthi, A. S. Jereesh, Yuansheng Liu · 2021 · Applied Soft Computing
  87. Management of COVID-19: current status and future prospects
    M. Kabir, R. Ahmed, R. Chowdhury, S. M. Iqbal, R. Paulmurugan, U. Demirci, W. Asghar · 2021 · Microbes and infection
  88. RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
    Hany Mansour Dabbous, Manal Hamdy El-Sayed, Gihan El Assal, Hesham A. Elghazaly, Fatma Soliman Elsayed Ebeid, Ahmed Fouad Sherief, Maha Elgaafary, Ehab Fawzy, Sahar Mohamed Hassany, Ahmed Radwan Riad et al. · 2021 · Scientific Reports · Retracted
  89. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19
    Jilei Zhang, Shari Garrett, Jun Sun · 2020 · Genes and Diseases
  90. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
    Morteza Arab‐Zozani, Soheil Hassanipour, Djavad Ghoddoosi-Nejad · 2020 · BMJ Open
  91. A case of successful treatment of severe COVID‐19 pneumonia with favipiravir and tocilizumab in post–kidney transplant recipient
    T. Thammathiwat, Somkanya Tungsanga, Kanitha Tiankanon et al. · 2020 · Transplant Infectious Disease
  92. COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts
    Z. Khan, Yusuf Karataş, A. F. Ceylan · 2020 · Le Pharmacien Hospitalier & Clinicien
  93. Cardiovascular manifestation and treatment in COVID-19
    Yen-Bo Su, Ming‐Jen Kuo, Ting‐Yu Lin, Chian‐Shiu Chien, Yi-Ping Yang, Shih‐Jie Chou, Hsin‐Bang Leu · 2020 · Journal of the Chinese Medical Association
  94. Experimental Pharmacotherapy for COVID-19: The Latest Advances
    Pasquale Pagliano, Giuliana Scarpati, Carmine Sellitto, Valeria Conti, Anna Maria Spera, Tiziana Ascione, Ornella Piazza, Amelia Filippelli · 2021 · Journal of Experimental Pharmacology
  95. COVID19- clinical presentation and therapeutic considerations
    Grace Kenny, Patrick W. G. Mallon · 2020 · Biochemical and Biophysical Research Communications
  96. SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment
    Khalil Khalaf, Natalia Papp, Jadzia Tin-Tsen Chou, Doris Hana, Andrzej Adam Mackiewicz, Mariusz Kaczmarek · 2020 · Frontiers in Immunology
  97. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
    Mitsuru Sada, T. Saraya, H. Ishii et al. · 2020 · Microorganisms
  98. Clinical management of coronavirus disease 2019 (COVID-19) in pregnancy: recommendations of WAPM-World Association of Perinatal Medicine
    Oluş Api, Cihat Şen, Marzena Dębska, Gabriele Saccone, F. D’Antonio, Nicola Volpe, Murat Yayla, Sertaç Esin, Şifa Turan, Asım Kurjak et al. · 2020 · Journal of Perinatal Medicine
  99. Favipiravir: A Possible Pharmaceutical Treatment for COVID-19
    H. Yanai · 2020 · Journal of Endocrinology and Metabolism
  100. Potential specific therapies in COVID-19
    Muhammad Hamdan Gul, Zin Mar Htun, Nauman Shaukat, Muhammad Imran, Ahmad Khan · 2020 · Therapeutic Advances in Respiratory Disease